Evaluation of Insulin Resistance of Individuals with MAFLD
Open Access
- 27 April 2023
- journal article
- research article
- Published by Bandirma Onyedi Eylul Universitesi in Hippocrates Medical Journal
- Vol. 3 (1) , 9-15
Abstract
Introduction: MAFLD is a new diagnosis that has been brought to the terminology in the last 2 years, and it is thought that the main mechanism underlying its development is Insulin Resistance (IR). In our study, it is planned to research the role of IR level in the etiology of patients with MAFLD. Method: 265 individuals with MAFLD are included in the study by examining their sub-parameters of case diagnosis. While 85 patients have T2DM, 180 patients are found to be Prediabetic. IR is calculated with HOMA-IR. The value of 2.5 and above is considered as high, and below 2.5 is considered as normal. The ratios of HOMA-IR levels and their relationship between waist circumference and BMI were examined. Findings: The value of HOMA-IR was found high in 60.6% of prediabetic MAFLDs, while it was normal in 39.4% of them. Age ((p=0.001; p<0.01) and waist circumference (p=0.028; p<0.05) in the T2DM group were found to be higher than the prediabetic group. Very weak positive correlation was found between HOMA-IR and BMI (r=0.223; p=0.003; p<0.01) and waist circumference (r=0.205; p=0.006; p<0.01) in the prediabetic group. In the T2DM group, there was a very weak positive correlation between BMI and HOMA-IR (r=0.254; p=0.019; p<0.05). Conclusion: In our study, IR was not detected in 39.4% of patients with MAFLD. This result leads us to think that insulin sensitizing agents may not be effective in this patient group in patients with normal IR levels. We think that these agents will not be effective in patients with normal IR levels. Our study should be supported with experimental and histological MAFLD studies.Keywords
This publication has 16 references indexed in Scilit:
- Physiopathological Treatment Approach and Position of Pioglitazone in Type 2 DiabetesAnadolu Kliniği Tıp Bilimleri Dergisi, 2017
- Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory studyDiabetologia, 2017
- Non‐alcoholic fatty liver disease ( NAFLD ) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetesDiabetes, Obesity and Metabolism, 2017
- The HOMA-Adiponectin (HOMA-AD) Closely Mirrors the HOMA-IR Index in the Screening of Insulin Resistance in the Brazilian Metabolic Syndrome Study (BRAMS)PLOS ONE, 2016
- Changes in hypertension prevalence, awareness, treatment, and control rates in Turkey from 2003 to 2012Journal Of Hypertension, 2016
- Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adultsDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2016
- Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adultsEuropean Journal of Epidemiology, 2013
- Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trialsDiabetologia, 2012
- Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in ratsJournal of Zhejiang University-SCIENCE B, 2006
- Reducing insulin resistance with metformin: the evidence todayDiabetes & Metabolism, 2003